NeOnc Technologies expects full enrollment in Phase 2a trial of NEO100-01
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 14 2025
0mins
Clinical Trial Enrollment: NeOnc Technologies anticipates full enrollment of 25 patients in its Phase 2a clinical trial for NEO100-01 by September, with only six patients remaining to be enrolled.
Therapeutic Focus: The trial investigates NEO100, an intranasal therapy targeting aggressive Grade III and IV gliomas, particularly those with IDH1 mutations, with data read-out expected in early 2026.
Analyst Views on NTHI
About NTHI
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
